CARMIEL, ISRAEL / ACCESS Newswire / September 11, 2025 / Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of ...

Baculovirus expression systems have emerged as an indispensable tool in the production of recombinant proteins, offering a robust platform for achieving high-level expression in insect cells. By ...

Learn how multichain biotherapeutics overcome manufacturing challenges with advanced expression vector design.

Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company, today announced that it has completed verification of its Entolimod™ cell line, the first step in establishing ...

Making proteins for research or therapies often starts with cell-line development. In many applications, genetic engineering is used to optimize a cell line for producing high levels of the intended ...

Grafting surface loops containing antibody epitopes of a poorly expressed flu neuraminidase protein onto a high-expressing, stable scaffold improves its production and stability for vaccine ...

WuXi Biologics launches HEK 293 Stable cell line platform WuXia293Stable for development and manufacturing of difficult-to-express molecules: Shanghai Tuesday, August 12, 2025, 11 ...

Dyadic’s management team welcomes the opportunity to connect with investors, analysts, and industry partners during the conferences. To request a meeting, please reach out to [email protected].

Protalix Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development, production, and commercialization of recombinant therapeutic proteins based on plant cell based ...

Explore how Claudin 18.2-specific antibodies are transforming population screening by enabling more effective detection of ...

CARMIEL, ISRAEL / ACCESS Newswire / September 11, 2025 / Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of ...